Share this article on:

Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine

Laurent, Christiana; Kouanfack, Charlesb; Koulla-Shiro, Sinatab; Njoume, Maguyc; Nkene, Yvette Mawambab; Ciaffi, Laurad; Brulet, Charlottec; Peytavin, Gillese; Vergne, Laurencea; Calmy, Alexandrad; Mpoudi-Ngolé, Eitelc; Delaporte, Erica

doi: 10.1097/QAD.0b013e328045c4d7
Research Letters

We assessed the long-term safety, effectiveness and quality of a fixed-dose combination of nevirapine, stavudine and lamivudine (triomune). HIV-1-infected adults initially enrolled in a one-year, open-label, single-arm, multicentre trial in Cameroon were followed for 2 years. Our results support the safety and effectiveness of the triomune combination for first-line treatment of HIV infection. Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high.

aIRD, UMR 145 (IRD/University of Montpellier 1), Montpellier, France

bCentral Hospital, Yaoundé, Cameroon

cProjet PRESICA, Military Hospital, Yaoundé, Cameroon

dMédecins Sans Frontières, Geneva, Switzerland

eLaboratoire de Toxicologie et de Dosage de Médicaments, Centre Hospitalier Universitaire Bichat Claude Bernard, Paris, France.

Received 2 May, 2006

Revised 24 May, 2006

Accepted 4 June, 2006

Correspondence to Christian Laurent, Institut de Recherche pour le Développement (UMR 145), 911 Avenue Agropolis, BP 64501, 34394 Montpellier cedex 5, France. E-mail:

© 2007 Lippincott Williams & Wilkins, Inc.